Home » Stocks » Bio-Path Holdings

Bio-Path Holdings, Inc. (BPTH)

Stock Price: $5.26 USD 1.17 (28.61%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $5.12 -0.14 (-2.66%) Oct 22, 7:59 PM

Stock Price Chart

Key Info

Market Cap 19.42M
Revenue (ttm) n/a
Net Income (ttm) -10.00M
Shares Out 3.69M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $5.26
Previous Close $4.09
Change ($) 1.17
Change (%) 28.61%
Day's Open 5.28
Day's Range 4.77 - 6.09
Day's Volume 49,211,664
52-Week Range 2.92 - 12.86

More Stats

Market Cap 19.42M
Enterprise Value 5.38M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 3.69M
Float 3.49M
EPS (basic) -2.96
EPS (diluted) -2.97
FCF / Share -2.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10,747
Short Ratio 0.13
Short % of Float 0.31%
Beta 2.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.95
Revenue n/a
Operating Income -10.07M
Net Income -10.00M
Free Cash Flow -10.15M
Net Cash 14.04M
Net Cash / Share 3.80
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.17%
ROE -58.93%
ROIC -685.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $5.26
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--184.62%-------
Gross Profit--0.040.01------
Operating Income-8.69-8.59-8.97-8.48-5.49-4.54-3.27-2.58-2.37-2.33
Net Income-8.60-8.58-7.02-6.75-5.47-4.52-3.27-2.58-2.36-2.08
Shares Outstanding2.660.600.500.460.450.450.360.300.270.24
Earnings Per Share-3.24-14.38-15.99-14.60-12.00-10.00-10.00-8.00-8.00-8.00
Operating Cash Flow-8.36-6.12-7.96-8.15-5.01-3.82-2.31-1.99-1.15-1.15
Capital Expenditures--0.02-0.54-0.34--0.12----
Free Cash Flow-8.36-6.14-8.50-8.49-5.01-3.94-2.31-1.99-1.15-1.15
Cash & Equivalents20.431.005.979.388.8513.863.550.530.950.24
Total Debt0.42---------
Net Cash / Debt20.011.005.979.388.8513.863.550.530.950.24
Book Value21.
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bio-Path Holdings, Inc.
Country United States
Employees 9
CEO Peter H. Nielsen

Stock Information

Ticker Symbol BPTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BPTH


Bio-Path Holdings operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.